Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer

Summary

This is a phase 3, multicenter, open-label, randomized active-controlled, parallel group to investigate the efficacy, safety and tolerability of intravenous balixafortide given with eribulin versus eribulin alone in the treatment of HER2 negative, Locally Recurrent or Metastatic Breast Cancer.

Timeline

Start

2019-05-30

Primary completion

2021-10-19

Completion

2021-10-19

Drugs

Indications